Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients

Clinical and Translational Oncology

Volumn 9, Issue 5, 2007, Pages 323-328

  Gonzalez Martin A ^a   Fernandez E ^a   Vaz, M A ^a   Burgos, J ^a   Lopez Garcia M ^a   Rodriguez Patron R ^a   Guillen C ^b   Mayayo, T ^a   Allona, A ^a   Arias, F ^a   Moyano, A ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c Hospital de Talavera de la Reina   (Spain)

Author keywords

Estramustine; Hormone resistant prostate cancer; Weekly docetaxel

Indexed keywords

DEXAMETHASONE; DOCETAXEL; ENOXAPARIN; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAXOID;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; GRANULOCYTE; HORMONE RESISTANCE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; LACRIMATION DISORDER; LEUKOCYTE; LONG TERM CARE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL; NAIL DYSTROPHY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; SHORT COURSE THERAPY; SIDE EFFECT; THROMBOCYTE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VOMITING; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; PROSTATE TUMOR; TIME; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ENOXAPARIN; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34848877498     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0060-1     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer Statistics 2007. CA Cancer J Clin 57:43-66
2. Small E, Halabi S, Dawson MA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033
3. Tannock IF, Osoba D, Stokler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer. A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764
4. Kantoff PW, Halabi S, Conaway M et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer. Results of the Cancer and Leukemia Group B9182 Study. J Clin Oncol 17:2506-2513
5. Mcdonnell TJ, Navone NM, Troncoso P et al (1997) Expression of Bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569-574
6. Stein CA (1999) Mechanisms of action of taxanes in prostate cancer. Semin Oncol 26[Suppl 17]:3-7
7. Dahllof B, Billstrom A, Cabral F et al (1993) Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53:4573-4581
8. Kreis W, Budman DR, Calabro A et al (1997) Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 79:196-202
9. Petrylak DP, Macarthur RB, O'Connor J et al (1999) Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967
10. Kreis W, Budman DR, Fetten J et al (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33-38
11. Savarese D, Halabi S, Hars V et al (2001) A phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: A final report of CALGB 9780. J Clin Oncol 19:2509-2516
12. Sinibaldi VJ, Carducci MA, Moore-Cooper S et al (2002) Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457-1465
13. Petrylak DP, Shelton GB, England-Owen C et al (2000) Response and preliminary survival results of a phase II study of docetaxel + estramustine in patients with androgen-independent prostate cancer (abstract). Proc Am Soc Clin Oncol 19:334a
14. Copur MS, Tarantolo SR, Hauke R et al (2000) Weekly estramustine, taxotere and dexamethasone in patients with hormone refractory prostate cancer (abstract). Proc Am Soc Clin Oncol 19:347a
15. Oudard S, Banu E, Beuzeboc P et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 20:3343-3351
16. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
17. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
18. Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232
19. Lubiniecki GM, Berlin JA, Weinstein RB et al (2004) Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: Results of a meta-analysis. Cancer 101:2755-2759
20. Nelius T, Klatte T, Yap R et al (2006) A randomized study of docetaxel and dexamethasone with low-or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int 98:580-585